Considering the potential impact of the condition on quality of life, the good benefit-risk profile of COSENTYX®, the limited alternatives available, the place of COSENTYX® in the therapeutic strategy, and the unlikely impact of COSENTYX® on public health, the committee considered the actual benefit of COSENTYX® to be ‘important’ in severe disease – proposing a reimbursement rate of 65% – and insufficient to justify reimbursement in other areas of the Marketing Authorisation. The 75 mg presentation of the drug was considered to provide no improvement in actual benefit (ASMR V) compared to the presentations already listed.